Pfizer tracks Real-World results of hair loss drug
NCT ID NCT06279221
Summary
This study is monitoring the long-term safety and effectiveness of Litfulo capsules in people with alopecia areata (an autoimmune hair loss condition) during real-world use. It will follow about 500 patients who are starting the medication for the first time. The main goals are to see how safe the drug is over time and to measure how many patients achieve significant hair regrowth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.